Drug Discovery Technologies

The global market for drug discovery technologies should grow from $69.8 billion in 2020 to $110.4 billion by 2025 with a compound annual growth rate (CAGR) of 9.6% for the period of 2020-2025.

Report Includes

• 31 data tables and 16 additional tables
• An overview of the global market for drug discovery technologies
• Estimation of the market size and analyses of global market trends, with data from 2019, 2020, and projections of compound annual growth rates (CAGRs) though 2025
• Evaluation of market forecast, pipeline analysis of new products, regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth
• Market share analysis of drug discovery technologies based on type, application, end-user, and region
• Information on reverse transcription-polymerase chain reaction (qRT-PCR), and next-generation sequencing (NGS) and coverage of bioanalytical instruments used for drug discovery
• Information on pharmacokinetics and pharmacodynamics, and classification of techniques used in drug discovery
• Discussion on bioinformatics as platform for drug discovery and comparison between proteomics and genomics drug discovery technology
• Detailed description of COVID-19 including symptoms and progression, its effect on medical tourism and insurance providers and coverage of government expenditure on COVID-19
• Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
• Comprehensive company profiles of major players of the industry, including Thermo Fisher Scientific, General Electric Co., Agilent, Illumina, Merck KGaA and Bio-Rad Laboratories

The global market for drug discovery technologies totaled $54.7 billion in 2017. The market should reach $85.8 billion by 2022, growing at a compound annual growth rate (CAGR) of 9.4% during 2017-2022.

Report Includes

• 60 data tables and 23 additional tables
• An overview of the global markets for drug discovery technologies
• Analyses of global market trends with data from 2015, 2016, and 2017, and projections of compound annual growth rates (CAGRs) through 2022
• A look at the current state of the drug discovery market, existing platforms and products on the market, and detailed analysis of the competitive environment, including new and potential venues for novel technologies and approaches
• Descriptions of various products, such as bioanalytical instruments, high-throughput screening devices, informatics, and microarrays
• Analyses of the main positive and negative factors in each sector of the market, potential future trends, and emerging technologies across different segments of the industry
• Comprehensive company profiles of major players in the market including Agilent Technologies Inc., Ametek Inc., Bayer Technology Services GMBH, Bruker Corp., Compugen Ltd. and GE Healthcare Lifesciences

The global market for drug discovery technologies reached nearly $39.5 billion and $46.5 billion in 2013 and 2014, respectively. This market is expected to grow at a compound annual growth rate (CAGR) of 11.3% to nearly $79.5 billion for the period 2014-2019. 

Report Includes

• An overview of the global markets for drug discovery technologies.
• Analyses of global market trends, with data from 2012-2014, and projections of CAGRs through 2019.
• A look at the current state of the drug discovery market, existing platforms and products on the market, and detailed analysis of the competitive environments including new, potential venues for novel technologies and approaches.
• Descriptions of various products such as bioanalytical instruments, high-throughput screening devices, informatics, and microarrays.
• Analyses of the main positive and negative factors in each sector of the market, potential future trends, and emerging technologies accross different segments of the industry.

The global market for drug discovery technologies and products reached $38.4 billion in 2011. It is expected to expand to $41.4 billion in 2012 and to $79.0 billion in 2017, a compound annual growth rate (CAGR) of 13.8% between 2012 and 2017.

• The global market for drug discovery technologies increased from $20.2 billion in 2006 to an estimated $22 billion in 2007. It should reach $32.5 billion by 2012, a compound annual growth rate (CAGR) of 8.2%.
• High throughput screening has the largest share of the market, worth an estimated $8.5 billion in 2007, and is expected to reach $12 billion by 2012, a CAGR of 7.1% over the forecast period.
• While informatics has the smallest share of the market, worth $725 million in 2007, the segment will see the largest CAGR of 15.7%, as its value rises to $1.5 billion by 2012.

REPORT HIGHLIGHTS

• New methods for drug discovery and delivery are receiving considerable attention in the pharmaceutical industry and in the media. Trial-and-error discovery methods have been replaced by focused combinatorial synthesis, high throughput systems, and other advanced systems. These new methods have produced agents that have entered clinical trials. As a result of the new technologies, costs and development times are falling, and knowledge about each new agent's mode of action has increased.
• This updated BCC study examines how the new drug discovery technologies have affected costs and drug development times. It also analyzes how new screening technologies, DNA microarrays, and increasingly sophisticated instruments will affect pharmaceutical discovery. An important section of the report analyzes market sizes and market growth for each technology. The report also includes interviews with executives in the instruments industry and the combinatorial chemistry industry.
• Molecular biology has given scientists detailed knowledge about basic and complex biological processes. One result of this new knowledge has been an explosion in the development of sophisticated pharmaceutical agents. For example, the number of drug candidates that have been screened in the last ten years has increased by three orders of magnitude: in 1990, approximately 500,000 drug compounds were screened; for the year 2000, that number is estimated at 1.5 billion.